Chronic lymphocytic leukaemia: A short overview

Annals of Oncology

Volumn 19, Issue SUPPL. 7, 2008, Pages

  Montserrat, E ^a   Moreno, C ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; CHLORAMBUCIL; CORTICOSTEROID; CYCLOPHOSPHAMIDE; FLUDARABINE; MITOXANTRONE; RITUXIMAB;

ALLOGENEIC STEM CELL TRANSPLANTATION; AUTOIMMUNE HEMOLYTIC ANEMIA; AUTOLOGOUS STEM CELL TRANSPLANTATION; B LYMPHOCYTE; CANCER INCIDENCE; CANCER STAGING; CHILL; CHROMOSOME ABERRATION; CHRONIC LYMPHATIC LEUKEMIA; CLINICAL FEATURE; CONFERENCE PAPER; DRUG CHOICE; DRUG FEVER; DRUG MEGADOSE; HUMAN; IMMUNE DEFICIENCY; IMMUNOGLOBULIN DEFICIENCY; IMMUNOPHENOTYPING; LYMPHOCYTOPENIA; MALIGNANT TRANSFORMATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROGNOSIS; RIGOR; WHOLE BODY RADIATION; B CELL LEUKEMIA; GENETICS; PATHOLOGY; REVIEW;

HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL;

EID: 53449089441     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdn460     Document Type: Conference Paper

References (89)

1. Müller-Hermelink HK, Catovsky D, Montserrat E, Harris NL. Chronic lymphocytic leukaemia/small lymphocytic lymphoma. In: Jaffe ES, Harris NL, Stein H, Vardiman JW (eds): WHO Classification of Tumors - Tumors of Haematopoietic and Lymphoid Tissues. Lyon: IARC Press 2001; 127-130.
2. Rozman C, Montserrat E. Chronic lymphocytic leukemia. N Engl J Med 1995; 333: 1052-1057.
3. Keating MJ, Chiorazzi N, Messmer B et al. Biology and treatment of chronic lymphocytic leukemia. Hematology 2003 (American Society of Hematology Education Program Book): 153-175.
4. Ries LAG, Eismer MP, Kosary CL et al. (eds). SEER Cancer Statistics Review, 1993-1997. Bethesda, MD: National Cancer Institute 2000.
5. Finch SC, Linet MS. Chronic leukaemias, Baillière's Clin Haematol 1992; 5: 27-56.
6. Landgren O, Gridley G, Check D, Caporaso NE, Morris Brown L. Acquired immune-related and inflammatory conditions and subsequent chronic lymphocytic leukaemia. Br J Haematol 2007; 139: 791-798.
7. Landgren O, Rapkin JS, Caporaso NE et al. Respiratory tract infections and subsequent risk of chronic lymphocytic leukemia. Blood 2007; 109: 2198-2201.
8. Cuttner J. Increased incidence of hematologic malignancies in first-degree relatives of patients with chronic lymphocytic leukemia. Cancer Invest 1992; 10: 103-109.
9. Rawstron C, Yuille R, Fuller R et al. Inherited predisposition to CLL is detectable as sub-clinical monoclonal B-lymphocyte expansion. Blood 2002; 100: 2289-2290.
10. Rawstron AC, Green MJ, Kuzmicki A et al. Monoclonal B lymphocytes with the characteristics of 'indolent' chronic lymphocytic leukemia are present in 3.5% of adults with normal blood counts. Blood 2002; 100: 635-639.
11. Messmer BT, Messmer D, Allen SL et al. In vivo measurements document the dynamic cellular kinetics of chronic lymphocytic leukaemia B cells. J Clin Invest 2005; 115: 755-764.
12. Chiorazzi N, Rai KR, Ferrarini M. Chronic lymphocytic leukemia. N Engl J Med 2005; 352: 804-815.
13. Döhner H, Stilgenbauer S, Benner A et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
14. Döhner H, Stilgenbauer S, Döhner K, Bentz M, Lichter P. Chromosome aberrations in B-cell chronic lymphocytic leukemia: Reassessment based on molecular cytogenetic analysis. J Mol Med 1999; 77: 266-281.
15. Döhner H, Stilgenbauer S, Fischer K, Bentz M, Lichter P. Cytogenetic and molecular cytogenetic analysis of B cell chronic lymphocytic leukemia: Specific chromosome aberrations identify prognostic subgroups of patients and point to loci for candidate genes. Leukemia 1997; 11 (Suppl 2): S19-S24.
16. Shanafelt TD, Witzig TE, Fink SR et al. Prospective evaluation of clonal evolution during long-term follow-up of patients with untreated early-stage chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 4634-4641.
17. Stilgenbauer S, Sander S, Bullinger L et al. Clonal evolution in chronic lymphocytic leukemia: Acquisition of high-risk genomic aberrations associated with unmutated VH, resistance to therapy, and short survival. Haematologica 2007; 92: 1242-1245.
18. Migliazza A, Bosch F, Komatsu H et al. Nucleotide sequence, transcription map, and mutation analysis of the 13q14 chromosomal region deleted in B-cell chronic lymphocytic leukemia. Blood 2001; 97: 2098-2104.
19. Bullrich F, Fujii H, Calin G et al. Characterization of the 13q14 tumor suppressor locus in CLL: Identification of ALT1, an alternative splice variant of the LEU2 gene. Cancer Res 2001; 61: 6640-6648.
20. Calin GA, Ferracin M, Cimmino A et al. A micro RNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med 2005; 353: 1793-1801.
21. Calin GA, Pekarsky Y, Croce CM. The role of microRNA and other non-coding RNA in the pathogenesis of chronic lymphocytic leukemia. Best Pract Res Clin Haematol 2007; 20: 425-437.
22. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
23. Damle RN, Wasil T, Fais F et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
24. Rozman C, Montserrat E, Viñolas N et al. Serum immunoglobulins in B-chronic lymphocytic leukaemia. Natural history and prognostic significance. Cancer 1988; 61: 279-283.
25. Kipps TJ, Carson DA. Autoantibodies in chronic lymphocytic leukemia and related systemic autoimmune diseases. Blood 1993; 81: 2475-2487.
26. Ward JH. Autoimmunity in chronic lymphocytic leukemia. Curr Treat Options Oncol 2001; 2: 253-257.
27. Myint H, Copplestone JA, Orchard J et al. Fludarabine-related autoimmune haemolytic anaemia in patients with chronic lymphocytic leukaemia. Br J Haematol 1995; 91: 341-344.
28. Juliusson G. Complications in the treatment of CLL with purine analogues. Hematol Cell Ther 1997; 39 (Suppl 1): S41-S44.
29. Richter MN. Generalized reticular cell sarcoma of lymph nodes associated with lymphatic leukaemia. Am J Pathol 1928; 4: 285-292.
30. Tsimberidou AM, O'Brien S, Khouri I et al. Clinical outcomes and prognostic factors in patients with Richter's syndrome treated with chemotherapy or chemoimmunotherapy with or without stem-cell transplantation. J Clin Oncol 2006; 24: 2343-2351.
31. Matolcsy A, Inghirami G, Knowles DM. Molecular genetic demonstration of the diverse evolution of Richter's syndrome (chronic lymphocytic leukemia and subsequent large cell lymphoma). Blood 1994; 83: 1363-1372.
32. Bruzzi JF, Macapinlac H, Tsimberidou AM et al. Detection of Richter's transformation of chronic lymphocytic leukemia by PET/CT. J Nucl Med 2006; 47: 1267-1273.
33. Mao Z, Quintanilla-Martinez L, Raffeld M et al. IgVH mutational status and clonality analysis of Richter's transformation: Diffuse large B-cell lymphoma and Hodgkin lymphoma in association with B-cell chronic lymphocytic leukemia (B-CLL) represent 2 different pathways of disease evolution. Am J Surg Pathol 2007; 31: 1605-1614.
34. Thornton PD, Bellas C, Santon A et al. Richter's transformation of chronic lymphocytic leukemia. The possible role of fludarabine and the Epstein-Barr virus in its pathogenesis. Leuk Res 2005; 29: 389-395.
35. Molica S. Infections in chronic lymphocytic leukemia: Risk factors and impact on survival, and treatment. Leuk Lymphoma 1994; 13: 203-214.
36. Morrison VA. Management of infectious complications in patients with chronic lymphocytic leukemia. Hematology Am Soc Hematol Educ Program 2007: 332-338.
37. Greene MH, Hoover RN, Fraumeni JF. Subsequent cancer in patients with chronic lymphocytic leukemia. A possible immunologic mechanism. J Natl Cancer Inst 1978; 61: 337-340.
38. Landgren O, Pfeiffer RM, Stewart L et al. Risk of second malignant neoplasms among lymphoma patients with a family history of cancer. Int J Cancer 2007; 120: 1099-1102.
39. Hisada M, Biggar RJ, Greene MH et al. Solid tumors after chronic lymphocytic leukemia. Blood 2001; 98: 1979-1981.
40. Hallek M, Cheson BD, Catovsky D. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: A report from the International Workshop on Chronic Lymphocytic Leukemia (IWCLL) updating the National Cancer Institute- Working Group (NCI-WG) 1996 guidelines. Blood 2008; In press.
41. Rai KR, Sawitsky A, Cronkite EP et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
42. Binet JL, Auquier A, Dighiero G et al. A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis. Cancer 1981; 48: 198-206.
43. Hamblin TJ, Davis Z, Gardiner A, Oscier DG, Stevenson FK. Unmutated IgV(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
44. Damle FIN, Wasil T, Fais F et al. Ig VH gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia, Blood 1999; 94: 1840-1847.
45. Krober A, Seiler T, Benner A et al. IgVH mutation status, CD38 expression level, genomic aberrations, and prognosis in chronic lymphocytic leukemia. Blood 2002; 100: 1410-1416.
46. Vasconcelos Y, Davi F, Levy V et al. Binet's staging system and VH genes are independent but complementary prognostic indicators in chronic lymphocytic leukemia. J Clin Oncol 2003; 21: 3928-3932.
47. Tobin G, Rosenquist R. Prognostic usage of V(H) gene mutation status and its surrogates markers and the role of antigen selection in chronic lymphocytic leukemia. Med Oncol 2005; 22: 217-228.
48. Thorsélius M, Knöber A, Murray F et al. Strikingly homologous immunoglobulin gene rearrangements and poor outcome in VH3-21-using chronic lymphocytic leukemia patients independent of geographic origin and mutational status. Blood 2006; 107: 2889-2894.
49. Hamblin TJ, Orchad JA Ibbotson RE et al. CD38 expression and immunoglobulin variable region mutations are independent prognostic variables in chronic lymphocytic leukemia, but CD38 expression may vary during the course of the disease. Blood 2002; 99: 1023-1029.
50. Montserrat E. New prognostic markers in CLL. Hematology Am Soc Hematol Educ Program 2006: 279-284.
51. Zucchetto A, Sonego P, Degan M et al. Surface-antigen expression profiling (SEP) in B-cell chronic lymphocytic leukaemia (B-CLL): identification of markers with prognostic relevance. J Immunol Meth 2005; 305: 20-32.
52. Gattei V, Bulian P, Del Principe MI et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008; 111: 865-873.
53. Rosenwald A, Alizadeh AA, Widhopf G et al. Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukemia. J Exp Med 2001; 194: 1639-1647.
54. Crespo M, Bosch F, Villamor N et al. ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med 2003; 348: 1764-1775.
55. Orchard A Ibbotson RE, Davis Z et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105-111.
56. Rassenti LZ, Huynh L, Toy TL et al. ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med 2004; 351: 893-901.
57. Del Principe MI, Del Poeta G, Buccisano F et al. Clinical significance of ZAP-70 protein expression in B-cell chronic lymphocytic leukemia. Blood 2006; 108: 853-861.
58. Krober A, Bloehdom J, Hafner S et al. Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol 2006; 24: 969-975.
59. Del Diudice I, Morilla A, Osuji N et al. Zeta-chain associated protein 70 and CD38 combined predict the time to first treatment in patients with chronic lymphocytic leukemia. Cancer 2005; 104: 2124-2132.
60. Schroers R, Griesinger F, Trümper L et al. Combined analysis of ZAP-70 and CD38 expression as a predictor of disease progression in B-cell chronic lymphocytic leukemia. Leukemia 2005; 19: 750-758.
61. Hus I, Podhorecka M, Bojarska-Junak A et al. The clinical significance of ZAP-70 and CD38 expression in B-cell chronic lymphocytic leukaemia. Ann Oncol 2006; 17: 683-690.
62. Keating MJ, O'Brien S, Albitar M et al. Early results of a chemoimmunotherapy regimen of fludarabine, cyclophosphamide, and rituximab as initial therapy for chronic lymphocytic leukaemia. J Clin Oncol 2005; 23: 1-8.
63. Wierda W, O'Brien S, Wen S et al. Chemoimmunotherapy with fludarabine, cyclophosphamide, and rituximab for relapsed and refractory chronic lymphocytic leukemia. J Clin Oncol 2005; 223: 40-47.
64. Byrd JC, Gribben JG, Peterson BL et al. Selected high-risk genetic features predict earlier progression following chemoimmunotherapy with fludarabine and rituximab in chronic lymphocytic leukemia: Justification for risk-adapted therapy. J Clin Oncol 2006; 24: 437-443.
65. Catovsky D, Richards S, Matutes E et al. Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. Lancet 2007; 370: 230-239.
66. Grever MR, Lucas DM, Dewald GW et al. Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997. J Clin Oncol 2007; 25: 799-804.
67. Lin KI, Tam CS, Abruzzo LV et al. IgVH mutational status does not affect complete remission rate but is associated with reduced remission duration in CLL patients treated with fludarabine, cyclophosphamide and rituximab (FCR)-based therapy [abstract]. Blood 2007; 110: (abstract 753).
68. Dighiero G, Maloum K, Desablens B et al. Chlorambucil in indolent chronic lymphocytic leukemia. N Engl J Med 1998; 338: 1506-1511.
69. Chemotherapeutic options in chronic lymphocytic leukemia: A meta-analysis of the randomized trials. CLL Trialists' Collaborative Group. J Natl Cancer Inst 1999; 91: 861-868.
70. Johnson S, Smith AG et al. The French Cooperative Group on CLL. Multicentre prospective randomized trial of fludarabine versus cyclophosphamide, doxorubicin, and prednisone (CAP) for treatment of advanced-stage chronic lymphocytic leukemia. Lancet 1996; 347: 1432-1438.
71. Rai KR, Peterson BL, Appelbaum FR et al. Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1750-1757.
72. Leporrier M, Chevret S, Cazin B et al. Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients. Blood 2001; 98: 2319-2325.
73. Eichhorst BF, Busch R, Hopfinger G et al. German CLL Study Group. Fludarabine plus cyclophosphamide versus fludarabine alone in first-line therapy of younger patients with chronic lymphocytic leukemia. Blood 2006; 107: 885-891.
74. Bosch F, Ferrer A, Villamor N et al. Fludarabine, cyclophosphamide and mitoxantrone as intial therapy of chronic lymphocytic leukemia: High response rate and disease eradication. Clin Cancer Res 2008; 14: 155-161.
75. Lundin J, Kimby E, Björkholm M et al. Phase II trial of subcutaneous anti-CD52 monoclonal antibody alemtuzumab (Campath-1H) as first-line treatment for patients with B-cell chronic lymphocytic leukemia (B-CLL). Blood 2002; 100: 768-773.
76. Hillmen P, Skotnicki AB, Robak T et al. Alemtuzumab compared with chlorambucil as first-line therapy for chronic lymphocytic leukemia. J Clin Oncol 2007; 25: 5616-5623.
77. Moreton P, Kennedy B, Lucas G et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after therapy with alemtuzumab is associated with prolonged survival. J Clin Oncol 2005; 23: 2971-2979.
78. Lozanski G, Heerema NA, Flinn IW et al. Alemtuzumab is an effective therapy for chronic lymphocytic leukemia with p53 mutations and deletions. Blood 2004; 103: 3278-3281.
79. Kennedy B, Rawstron A, Carter C et al. Campath-1H and fludarabine in combination are highly active in refractory chronic lymphocytic leukemia. Blood 2002; 99: 2245-2257.
80. Elter T, Borchmann P, Schulz H et al. Fludarabine in combination with alemtuzumab is effective and feasible in patients with relapsed or refractory B-cell chronic lymphocytic leukemia: Results of a phase II trial. J Clin Oncol 2005; 23: 7024-7031.
81. Dreger P, Montserrat E. Autologous and allogeneic stem cell transplantation for chronic lymphocytic leukemia. Leukemia 2002; 16: 985-992.
82. Moreno C, Villamor N, Colomer D et al. Allogeneic stem-cell transplantation may overcome the adverse prognosis of unmutated VH gene in patients with chronic lymphocytic leukemia. J Clin Oncol 2005; 23: 3433-3438.
83. Gribben JG, Zahrieh D, Stephans K et al. Autologous and allogeneic stem cell transplantations for poor-risk chronic lymphocytic leukemia. Blood 2005; 106: 4389-4396.
84. Sorror ML, Storer BE, Maloney DG et al. Outcomes after allogeneic hematopoietic cell transplantation with nonmyeloablative or myeloablative conditioning regimens for treatment of lymphoma and chronic lymphocytic leukemia. Blood 2008; 111: 446-452.
85. Ritgen M, Lange A, Stilgenbauer S et al. Unmutated immunoglobulin variable heavy-chain gene status remains an adverse prognostic factor after autologous stem cell transplantation for chronic lymphocytic leukemia. Blood 2003; 101: 2049-2053.
86. Dreger P, Stilgenbauer S, Benner A et al. The prognostic impact of autologous stem cell transplantation in patients with chronic lymphocytic leukemia: A risk-matched analysis based on the VH gene mutational status. Blood 2004; 103: 2850-2858.
87. Dreger P, Corradini P, Kimby E et al. Chronic Leukemia Working Party of the EBMT. Indications for allogeneic stem cell transplantation in chronic lymphocytic leukemia: The EBMT transplant consensus. Leukemia 2007; 21: 12-17.
88. Dreger P, Brand R, Hansz J et al. Treatment-related mortality and graft-versus-leukemia activity after allogeneic stem cell transplantation for chronic lymphocytic leukemia using intensity-reduced conditioning. Leukemia 2003; 17: 841-848.
89. Montserrat E, Moreno C, Esteve J et al. How I treat refractory CLL. Blood 2006; 107: 1276-1283.